A novel noninvasive formula for predicting cirrhosis in patients with chronic hepatitis C.

por Masanori Atsukawa, Akihito Tsubota, Chisa Kondo, Sawako Uchida-Kobayashi, Koichi Takaguchi, Akemi Tsutsui, Akito Nozaki, Makoto Chuma, Isao Hidaka, Tsuyoshi Ishikawa, Motoh Iwasa, Yasuyuki Tamai, Maki Tobari, Kentaro Matsuura, Yoshihito Nagura, Hiroshi Abe, Keizo Kato, Kenta Suzuki, Tomomi Okubo, Taeang Arai, Norio Itokawa, Hidenori Toyoda, Masaru Enomoto, Akihiro Tamori, Yasuhito Tanaka, Norifumi Kawada, Yoshiyuki Takei, Katsuhiko Iwakiri
Publicado 2021

Impact of modified albumin–bilirubin grade on survival in patients with HCC who received lenvatinib

por Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, Masanori Atsukawa, Masashi Hirooka, Kunihiko Tsuji, Toru Ishikawa, Koichi Takaguchi, Kazuya Kariyama, Ei Itobayashi, Kazuto Tajiri, Noritomo Shimada, Hiroshi Shibata, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Shinya Fukunishi, Hideko Ohama, Kazuhito Kawata, Joji Tani, Shinichiro Nakamura, Kazuhiro Nouso, Akemi Tsutsui, Takuya Nagano, Tanaka Takaaki, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Kouji Joko, Yohei Koizumi, Yoichi Hiasa, Real-life Practice Experts for HCC (RELPEC) Study Group and the HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)
Publicado 2021

Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study

por Atsushi Hiraoka, Takashi Kumada, Toshifumi Tada, Joji Tani, Kazuya Kariyama, Shinya Fukunishi, Masanori Atsukawa, Masashi Hirooka, Kunihiko Tsuji, Toru Ishikawa, Koichi Takaguchi, Ei Itobayashi, Kazuto Tajiri, Noritomo Shimada, Hiroshi Shibata, Hironori Ochi, Kazuhito Kawata, Satoshi Yasuda, Hidenori Toyoda, Tomoko Aoki, Takaaki Tanaka, Hideko Ohama, Kazuhiro Nouso, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Taeang Arai, Tomomi Okubo, Michitaka Imai, Yohei Koizumi, Shinichiro Nakamura, Koji Joko, Yoichi Hiasa, Masatoshi Kudo, The Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)
Publicado 2021